EUR 47 million committed by fund initiators Ascenion and Goethe-University together with the European Investment Fund (EIF), Evotec, and other investors
Focus on high-potential, early-stage life-science start-ups and projects, sourced from Ascenion’s and Innovectis’ partner institutions and other European academic institutions
15 + 5 years timeframe enables the partners – and the institutions they represent – to participate in future profits
25 August 2021, Munich – Cardior Pharmaceuticals has closed a Series B financing round totalling EUR 64 million (USD 76 million). The round was led by…
Simultaneously Closes Strategic Growth Investment from Ampersand Capital to Create a Leading Provider of Genomic and Cell and Tissue Analysis Products…
A consortium of nine partners from five European countries, led by the Helmholtz Zentrum München, will work together with a transdisciplinary approach…
Berlin Cures, one of Ascenion’s investment portfolio companies, has announced the start of a clinical trial with its lead candidate BC007. The Phase I…